Project Grant R01EB038224
- Federal Grant Award Summary The University of Miami received a $1.28M Project Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), with an award date of August 1, 2025 and completion deadline of April 30, 2029. This research initiative will develop and validate magnetic particle imaging (MPI) technology for quantitative, non-invasive monitoring of...
- Federal Grant Award Summary The University of Southern California received a $656,500 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective April 1, 2026, through January 31, 2031. The award supports research into technologies for studying and controlling cell patterning and differentiation in multicellular development, with a case study focused on engineering multilayered...
- Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), awarded $471,967 to the Regents of the University of Minnesota on May 1, 2026, with completion targeted for February 28, 2030. This Project Grant supports the development of dual density-dependent molecular AND gate binders—engineered bispecific targeting ligands designed to...
- Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded the University of Missouri System $418,043 under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) for a two-year project grant running from August 1, 2025, through July 31, 2027. The project deliverables center on the design and development of a self-tunable messenger RNA (mRNA) circuit capable of sustained, precise regulation...
- Federal Grant Award Summary Sanford Research received a $456,500 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective March 1, 2026, through January 31, 2031. This award supports fundamental research into the regulation of nucleocytoplasmic compartmentalization, specifically examining the structure and function of the nuclear envelope—a critical cellular structure that...
- Federal Project Grant Award Summary The University of Minnesota's Regents received a $398,144 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective April 1, 2026, through January 31, 2031. This award funds research to develop immunocompetent tissue models that replicate the behavior of tissue-resident macrophages with controllable inflammatory states. The project employs human...
- Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded the University of Notre Dame a $662,737 Project Grant (CFDA 93.286: Discovery and Applied Research for Technological Innovations to Improve Human Health) on March 5, 2026, to develop an innovative hybrid multi-material and multi-method autonomous printing (HM2AP) technology. The project, extending through February 28, 2030, will integrate aerosol jet sacrificial printing with extrusion...
- Federal Grant Award Summary The University of Nebraska Board of Regents received a $2.04 million Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded August 8, 2025, with completion targeted for July 31, 2029. This award supports fundamental research investigating the ARP2/3 complex—a critical protein assembly system essential to cellular processes including cell migration, tissue...
- Federal Grant Award Summary North Dakota State University received a $543,750 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on September 8, 2025, with a completion date of September 7, 2028. The grant supports fundamental biomedical research investigating the structural mechanisms of regulated intramembrane proteolysis in gram-negative bacteria, specifically examining how a site-1...
- Federal Project Grant Award Summary Iowa State University of Science and Technology received a $182,558 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), effective May 6, 2026 through February 28, 2029. The funded research develops a bioinspired strategy for designing personalized combination immunoregulatory therapeutics by...
The University of South Dakota received a $2.8M Project Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), effective June 1, 2026 through May 31, 2030. The award funds development of engineered mesenchymal stem cell (MSC) therapeutics using synthetic biology approaches. Specifically, the project will create Autonomous Impairment-inducible MSCs (AIMSCs)—cells integrated with synthetic genetic circuits that autonomously detect disease or stress signals within damaged tissues and initiate targeted therapeutic responses. The research includes embedding dual intracellular feedback control mechanisms and endogenous microRNA-based safety switches to ensure the engineered cells respond appropriately to microenvironmental conditions in real time. This research addresses a significant clinical limitation: the poor survival and reduced regenerative capability of MSCs in hostile tissue microenvironments, which currently undermines therapeutic efficacy. The AIMSC platform represents a next-generation MSC therapy designed to enhance cell survival and deliver targeted pathology treatment by combining sensing, decision-making, and effector capabilities within the engineered cells themselves. The project will employ synthetic biology, genetic engineering, and related technologies to develop and validate this cellular theranostic platform, with proof-of-concept demonstrations planned across two specific aims.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.8m | 5/22/26 |